DMH-Based Plan Evaluation and Inverse Optimization in Radiotherapy
The hypotheses of the study are as follows: * Mass-based inverse optimization in radiotherapy treatment planning will result in a reduction of normal tissue and organs at risk (OAR) doses for desired prescription therapeutic doses to the targets. * Dose-mass histograms (DMHs) may be more relevant to radiotherapy treatment planning and treatment plan assessment than the standard of care, realized through dose-volume histograms (DVHs)
Checked against the public recordLast updated Feb 5, 2020 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Health Services Research
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- University of Miami
- Interventions being studied
- Device: CT Scan
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Patients must have histologically confirmed head-and-neck, lung, or prostate tumors. * Patients who will be treated with radiation therapy or concurrent chemoradiation therapy. * Gross Tumor Volume (GTV) or resection cavity must be visible on CT such that it can be delineated as a target for radiotherapy. * Patients who are able to understand the investigational nature of this study and agree to sign a written informed consent document. Exclusion Criteria: * Pregnant or nursing women will not participate. Women of reproductive potential must be offered a pre-treatment pregnancy test and informed of the need to practice an effective contraceptive method during the therapy. * Patients younger than 18 years. * Patients whose size and weight would not allow CT scanning. * No vulnerable populations (fetuses, pregnant women, children, prisoners) will be included in this study.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of MiamiMiami, Florida
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Feb 5, 2020. Always confirm current availability with the study team.